Videregen Private
Videregen Limited is a regenerative medicine company that aims to address the chronic shortage of organs for transplantation. Using their proprietary technology, they produce biological scaffolds to which a patient's own stem cells are added, creating personalized organ replacements. Initially focused on diseases of the trachea and bowel, Videregen aims to develop the world's first commercially available organ replacements for these conditions. Their goal is to reduce healthcare costs and improve the quality of life for patients. Additionally, Videregen is also working on translating advances in thymus stem cell science to target diseases characterized by thymus dysfunction, thymus aging, T cell development, and autoimmunity. Their BioThymus technology platform has the potential to rejuvenate thymus function, treat athymia, reduce autoimmunity, and create tolerance to organ transplants.
